Olov Wiklund

Olov Wiklund's AcademicInfluence.com Rankings

Olov Wiklund

Computer Science

#7426

World Rank

#7822

Historical Rank

Computational Linguistics

#1477

World Rank

#1493

Historical Rank

Machine Learning

#2730

World Rank

#2765

Historical Rank

Artificial Intelligence

#3026

World Rank

#3072

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Olov Wiklund Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Olov Wiklund's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) (3648)
[ESC/EAS Guidelines for the management of dyslipidaemias]. (2011) (3612)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (3071)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016) (1974)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) (1786)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (1103)
T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. (1995) (988)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis (2002) (971)
Low-density lipoproteins cause atherosclerotic cardiovascular disease (2018) (936)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit (2007) (911)
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2012) (904)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention (2016) (657)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) (630)
'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. (2011) (596)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) (545)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med (2016) (489)
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. (2016) (476)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) (470)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. (2014) (442)
Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. (1998) (333)
Evidence of hypoxic areas within the arterial wall in vivo. (1999) (302)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2011) (290)
Statin use and non-alcoholic steatohepatitis in at risk individuals. (2015) (288)
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells (2014) (285)
Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. (2003) (279)
Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. (1996) (249)
Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. (1993) (246)
Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. (2009) (241)
Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. (2012) (236)
Arterial wall thickness in familial hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. (1992) (235)
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018) (221)
Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. (1993) (213)
Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. (1997) (211)
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia (1990) (199)
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. (2002) (186)
Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. (1997) (184)
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia (2018) (183)
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. (2015) (180)
Hypoxia Converts Human Macrophages Into Triglyceride-Loaded Foam Cells (2006) (176)
Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. (1990) (168)
Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. (1997) (167)
Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. (1996) (166)
Early prediction of acute myocardial infarction from clinical history, examination and electrocardiogram in the emergency room. (1991) (160)
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk (2016) (159)
Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. (1986) (158)
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medi (2016) (151)
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. (2001) (150)
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. (2018) (148)
Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. (1988) (144)
Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. (1996) (144)
Multivariate Analyses of Serum Apolipoproteins and Risk Factors in Relation to Acute Myocardial Infarction (1981) (143)
Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. (2003) (135)
Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. (1994) (134)
Cholesterol: a renal risk factor in diabetic nephropathy? (1993) (130)
Effect of Controlled Release/Extended Release Metoprolol on Carotid Intima-Media Thickness in Patients With Hypercholesterolemia: A 3-Year Randomized Study (2002) (123)
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia (1993) (123)
Effects of simvastatin and atorvastatin on inflammation markers in plasma (2002) (117)
Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. (1998) (116)
A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin (2003) (114)
Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. (1995) (113)
ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. (2006) (112)
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM (2019) (111)
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan (2009) (107)
Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules, and Phospholipase A2 (2001) (105)
Role of the Low Density Lipoprotein Receptor in Penetration of Low Density Lipoprotein into Rabbit Aortic Wall (1985) (103)
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis (2016) (103)
A common polymorphism in the interleukin-6 gene promoter is associated with overweight (2004) (101)
Oxysterols induce interleukin‐1β production in human macrophages (2002) (97)
Hypoxia Increases LDL Oxidation and Expression of 15-Lipoxygenase-2 in Human Macrophages (2004) (94)
N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. (1996) (92)
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. (2016) (90)
Plasma Levels of β-Amyloid(1-40), β-Amyloid(1-42), and Total β-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins (2004) (89)
The new joint EAS/ESC guidelines for the management of dyslipidaemias. (2011) (87)
The assembly and secretion of apoB 100 containing lipoproteins in Hep G2 cells. Evidence for different sites for protein synthesis and lipoprotein assembly. (1990) (85)
Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. (1998) (85)
On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. (1996) (84)
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. (2016) (83)
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease (2007) (83)
The nicotine inhaler in smoking cessation. (1997) (83)
Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages. (2003) (81)
Frontiers in cardiovascular science. Quantitative measurements of atherosclerotic manifestations in humans. (1992) (80)
Low‐grade inflammation, endothelial activation and carotid intima‐media thickness in type 2 diabetes (2004) (76)
Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors. Apolipoprotein A-I levels in male survivors of myocardial infarction. (1980) (71)
Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. (1993) (71)
Alphalipoprotein cholesterol levels in relation to acute myocardial infarction and its risk factors. (1980) (69)
CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. (2006) (69)
Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. (1997) (68)
Modification of copper-catalyzed oxidation of low density lipoprotein by proteoglycans and glycosaminoglycans. (1991) (65)
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. (2020) (65)
Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance (2004) (64)
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. (2008) (64)
Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias (2017) (63)
Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. (1996) (62)
Cholesterol reduction and clinical benefit. Are there limits to our expectations? (1997) (61)
Interleukin-18 as a Predictor of Future Events in Patients With Acute Coronary Syndromes (2010) (59)
Guía de la ESC/EAS sobre el manejo de las dislipemias (2011) (59)
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. (2006) (59)
Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica (2016) (58)
Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing (2014) (58)
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. (1993) (58)
Major role of HSP70 as a paracrine inducer of cytokine production in human oxidized LDL treated macrophages. (2006) (57)
C‐reactive protein, interleukin‐6, secretory phospholipase A2 group IIA and intercellular adhesion molecule‐1 in the prediction of late outcome events after acute coronary syndromes (2007) (57)
Serum lipoproteins in acromegaly before and 6‐15 months after transsphenoidal adenomectomy (1994) (56)
Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy (1993) (56)
Copper induces the expression of cholesterogenic genes in human macrophages. (2003) (54)
Ten‐year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia (2000) (53)
Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. (2014) (53)
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. (2004) (53)
Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. (1987) (52)
Lack of correlation between the apolipoprotein B XbaI polymorphism and blood lipid levels in a Swedish population. (1989) (52)
Modifications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. (1991) (52)
Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. (2008) (51)
Molecular cloning of human apolipoprotein B cDNA. (1985) (48)
Increased Interleukin‐6 levels in pituitary‐deficient patients are independently related to their carotid intima‐media thickness (2003) (47)
Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction (1989) (46)
Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels (1990) (46)
Serum lipids and apolipoprotein levels in women with acute myocardial infarction. (1988) (46)
Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. (1998) (45)
Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle‐aged men (1994) (45)
Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix. (1999) (45)
Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population. (2004) (44)
15‐Lipoxygenase‐2 is expressed in macrophages in human carotid plaques and regulated by hypoxia‐inducible factor‐1α (2010) (44)
Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease (2002) (43)
Mapping of ATP, Glucose, Glycogen, and Lactate Concentrations Within the Arterial Wall (2003) (43)
Post‐transcriptional regulation of VEGF expression by oxidised LDL in human macrophages (2002) (43)
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. (2007) (42)
25-hydroxycholesterol induces lipopolysaccharide-tolerance and decreases a lipopolysaccharide-induced TNF-alpha secretion in macrophages. (2001) (41)
Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. (1995) (41)
Uptake and degradation of low density lipoproteins in atherosclerotic rabbit aorta: role of local LDL modification. (1991) (41)
Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. (2001) (41)
Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis (2008) (40)
Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. (2006) (39)
Pulse-chase studies of the synthesis of apolipoprotein B in a human hepatoma cell line, Hep G2. (1985) (39)
Alpha-lipoprotein cholesterol concentration in relation to subsequent myocardial infarction in hypercholesterolemic men. (1980) (39)
Physical training after percutaneous coronary intervention in patients with stable angina: effects on working capacity, metabolism, and markers of inflammation (2010) (39)
Prognosis in hypertensives with acute myocardial infarction (1992) (38)
Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy (2013) (38)
Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors--determination of apolipoprotein D. (1980) (37)
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. (2003) (37)
Arachidonate 15-Lipoxygenase Type B Knockdown Leads to Reduced Lipid Accumulation and Inflammation in Atherosclerosis (2012) (35)
Atherosclerosis basic mechanisms. (2009) (33)
Effect of Short‐Term Beta Blockade on Serum Lipid Levels and on the Interaction of LDL with Human Arterial Proteoglycans (1990) (33)
LDL particle size in relation to intima‐media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia (2000) (32)
15-Lipoxygenase-2 expression in human macrophages induces chemokine secretion and T cell migration. (2008) (32)
Expression of Platelet-Activating Factor Receptor in Human Carotid Atherosclerotic Plaques: Relevance to Progression of Atherosclerosis (2000) (32)
A method for the assessment of hypoxia in the arterial wall, with potential application in vivo. (1996) (30)
Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. (2000) (30)
Computerized measurement of LDL particle size in human serum. Reproducibility studies and evaluation of LDL particle size in relation to metabolic variables and the occurrence of atherosclerosis. (1999) (29)
Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia (2008) (29)
Identification of genes predominantly expressed in human macrophages. (2004) (29)
Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques (2005) (28)
Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. (1996) (28)
Glucose impairs B‐1 cell function in diabetes (2013) (27)
Binding parameters and concentration modulate formation of complexes between LDL and arterial proteoglycans in serum. (1989) (26)
Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. (2016) (26)
Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. (2002) (26)
Augmented levels of CD44 in macrophages from atherosclerotic subjects: a possible IL-6-CD44 feedback loop? (2007) (26)
Release of protein as well as activity of MMP‐9 from unstable atherosclerotic plaques during percutaneous coronary intervention (2007) (25)
Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia (2008) (25)
Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. (1991) (25)
Serum triglycerides and HDL cholesterol--major predictors of long-term survival after coronary surgery. (1994) (25)
Structure and biosynthesis of apolipoprotein B. (1987) (25)
Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning (2020) (24)
Butylated hydroxytoluene and N-acetylcysteine attenuates tumor necrosis factor-alpha (TNF-alpha) secretion and TNF-alpha mRNA expression in alveolar macrophages from human lung transplant recipients in vitro. (1998) (24)
Quantitation of human serum apolipoprotein A-I by electroimmunoassay. Studies on some techniques for standardization of the assay and determination of serum apolipoprotein A-I levels in a random population sample of middle-aged men. (1980) (24)
Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling. (2001) (23)
RFLPs for the human apolipoprotein B gene: HincII and PvuII. (1986) (23)
Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide. (1983) (22)
Stoichiometric binding of apolipoprotein B-specific monoclonal antibodies to low density lipoproteins. (1985) (22)
Measurement of antioxidant activity in lipoproteins using enhanced chemiluminescence. (1994) (21)
Xbal restriction fragment length polymorphism of apolipoprotein B in Swedish myocardial infarction patients (1989) (20)
LDL‐associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome (2011) (20)
Expression profiling of macrophages from subjects with atherosclerosis to identify novel susceptibility genes. (2008) (20)
Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment (2015) (19)
Occurrence of angina pectoris prior to acute myocardial infarction and its relation to prognosis. (1993) (19)
Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)) (2019) (19)
Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment (2006) (19)
Seasonal variations in serum lipid and apolipoprotein levels evaluated by periodic regression analyses. (1982) (19)
Transfer of lipoproteins from plasma to the cell populations of the normal and atherosclerotic arterial tissue. (1990) (19)
A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. (2000) (18)
The COBLL1 C allele is associated with lower serum insulin levels and lower insulin resistance in overweight and obese children (2013) (18)
Influx and Cellular Degradation of Low Density Lipoproteins in Rabbit Aorta Determined in an In Vitro Perfusion System (1987) (18)
Isolation of cell populations from arterial tissue, using monoclonal antibodies and magnetic microspheres. (1991) (17)
Human macrophages limit oxidation products in low density lipoprotein (2005) (17)
Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls. (1997) (17)
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk (2018) (17)
Dissociation of the Inflammatory Reaction following PCI for Acute Myocardial Infarction. (2007) (17)
Inhibitory effects of N‐acetylcysteine on scavenger receptor class A expression in human macrophages (2002) (17)
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression (2003) (16)
Oxidised LDL decreases VEGFR-1 expression in human monocyte-derived macrophages. (2003) (15)
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). (1999) (15)
A bioluminescence method for the mapping of local ATP concentrations within the arterial wall, with potential to assess the in vivo situation. (1999) (14)
Cell adhesion molecules and secretory type II phospholipase A2 in relation to carotid atherosclerosis in patients with hypercholesterolaemia (2001) (14)
Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels. (1999) (13)
Multifactorial treatment of hypertensive men at high cardiovascular risk and low‐density lipoprotein cholesterol affinity to human arterial proteoglycans (1996) (13)
Characteristics and prognosis of patients with acute myocardial infarction in relation to whether they were treated in the coronary care unit or in another ward. (1992) (13)
Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. (1994) (11)
Low frequency of the common Norwegian and Finnish LDL‐receptor mutations in Swedish patients with familial hypercholesterolaemia (1998) (11)
XbaI restriction fragment length polymorphism of apolipoprotein B in Swedish myocardial infarction patients. (1989) (11)
A new microimmunoassay for apolipoprotein B in arterial tissue. Studies on peroperative human biopsies. (1986) (11)
High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease (2019) (11)
How can we prevent cardiovascular disease in diabetes (2007) (11)
Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a "mock" FL3 channel in flow cytometry. (1997) (10)
Effects of injury on apoB kinetics and concentration in rabbit aorta. (1995) (10)
Pathogenesis and treatment of diabetic vascular disease – illustrated by two cases (2006) (10)
Lecithin : cholesterol acyl transfer (LACT) and fatty acid composition of lecithin and cholesterol esters in young male myocardial infarction survivors. (1979) (10)
Think Again About Cholesterol Survey. (2015) (10)
New prospects for PCSK9 inhibition? (2018) (10)
Guidelines on CVD prevention: confusing or complementary? (2013) (9)
Cationic polypeptides modulate in vitro association of low density lipoprotein with arterial proteoglycans, fibroblasts, and arterial tissue. (1990) (9)
Guía ESC/EAS 2019 sobre el tratamiento de las dislipemias: modificación de los lípidos para reducir el riesgo cardiovascular (2020) (8)
Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. (2017) (8)
The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals. (2013) (8)
Human liver RNA‐programmed in vitro synthesis of a polypeptide related to human apolipoprotein B (1983) (8)
Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (7)
Alphalipoprotein cholesterol and arterial cholesterol in human uterine arteries. (1980) (7)
Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification. (1998) (7)
Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction (1989) (7)
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (6)
Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism. (1977) (6)
Quantification of plasma lipids and apolipoproteins in British Halflop rabbits. A comparison between normocholesterolemic rabbits, hypercholesterolemic rabbits (modified WHHL rabbits) and rabbits fed an atherogenic diet. (1988) (6)
Evidence for a structural relationship between apoB75kDa and human plasma apolipoprotein B 100, from translation of human liver mRNA in vitro and immunochemical studies with monoclonal and polyclonal antibodies. (1984) (6)
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (6)
Myocardial release of FKBP12 and increased production of FKBP12.6 in ischemia and reperfusion experimental models. (2009) (6)
Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). (2014) (6)
Skin cholesterol and DNA in young patients with myocardial infarction. (2009) (5)
Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The treat-to-target study (3T) (2000) (5)
The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia (2011) (5)
Biochemical typing of hyperlipoproteinemia. The development of a nomogram. (1975) (5)
Direct assessment of lipoprotein outflow from in vivo-labeled arterial tissue as determined in an in vitro perfusion system. (1998) (5)
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition and increased susceptibility for sphingomyelinase (2008) (5)
Understanding the Patient Perception of Statin Experience: A Qualitative Study (2019) (4)
Aortic intimal lipid content and serum lipoproteins in patients undergoing coronary by-pass surgery as related to clinical prognosis. (1988) (4)
Glucose tolerance, plasma insulin and α‐lipoproteins in young male myocardial infarction survivors compared with controls matched on serum cholesterol concentration (1979) (4)
One-year mortality rate after discharge from hospital in relation to whether or not a confirmed myocardial infarction was developed. (1991) (4)
Oxysterols present in atherosclerotic tissue modulate the expression of lipoprotein lipase mRNA in human monocyte-derived macrophages (1994) (3)
Alpha lipoproteins in relation to myocardial infarction (1978) (3)
Arterial cholesterol and DNA contents in relation to serum lipids and apolipoproteins. Studies on cystic artery biopsies. (1982) (3)
Local delivery of antithrombin inhibits platelet deposition after balloon injury in a porcine coronary model (1998) (3)
2.P.325 CD36 is a specific platelet receptor for native and modified low-density lipoproteins (1997) (3)
Quantitative Measurements of Atherosclerotic Manifestations in Humans (2005) (2)
Apolipoprotein B in human aortic biopsies in relation to serum lipids and lipoproteins. (1989) (2)
Treating lipids in cardiovascular disease: new directions (2001) (2)
Lack of correlation between the serum level of lipoprotein (a) and restenosis after coronary angioplasty (1992) (2)
Pharmacological lipid lowering for prevention of cardiovascular disease in older adults (2014) (2)
Oxidized Low Density Lipoprotein Inhibits Lipopolysaccharide-induced Binding of Nuclear Factor – k B to DNA and the Subsequent Expression of Tumor Necrosis Factor – a and Interleukin-1 b in Macrophages (2013) (1)
Phospholipase A2 in the pathogenesis of cardiovascular disease (2003) (1)
25-Hydroxycholesterol increases a hypoxia induced IL-8 protein secretion in human macrophages (2000) (1)
There is no effect on remodeling of vascular wall 4 weeks after local delivery of antithrombin in a porcine model of coronary overstretching (2001) (1)
PO19-557 IS UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR A BIOMARKER OF PLAQUE VULNERABILITY IN SYMPTOMATIC CAROTID ATHEROSCLEROSIS? (2007) (1)
Mutations in the LDR-receptor gene in Swedish patients with familial hypercholesterolemia (2000) (1)
Evidence of ATP and glucose depleted areas within the atherosclerotic plaque in vivo (2000) (1)
Recombinant human insulin-like growth factor 1 decreases serum lipoprotein(a) concentrations in man (1995) (1)
WO10-OR-5 INCREASED LIPOLYSIS BY SECRETORY PHOSPHOLIPASE A2 GROUP V OF LIPOPROTEINS FROM SUBJECTS WITH TYPE 2 DIABETES AND THE METABOLIC SYNDROME (2007) (1)
P221 lipid droplets in human macrophages recruit cytosolic phospholipase A2 and promote secretion of inflammatory mediators (2010) (1)
In Memoriam: Sven-Olof Olofsson (1947–2011)⋆ (2012) (0)
Hypercholesterolemias, Familial Defective ApoB (FDB) and LDL Receptor Defects (2004) (0)
The IRS 1 rs 2943641 Variant and Risk of Future Cancer Among Morbidly Obese (2018) (0)
In Memoriam: German Camejo (1936-2021). (2021) (0)
Pro- and anti-oxidative activities of human monocytes: Effect of concentration of oxidatively modified low density lipoprotein (2000) (0)
GuidelinesESC/EAS Guidelines for the Management of Dyslipidaemias (2013) (0)
Modification of lipoproteins in the intimal extracellular compartment that can contribute to atherogenesis (1990) (0)
LDL-particle size and insulin resistance, measured with the hyperinsulinemic clamp technique (2000) (0)
Oxidised LDL increases the VEGF expression in human macrophages (2000) (0)
Contents Vol. 111, 2008 (2008) (0)
25-hydroxycholesterol modulates an inflammatory response in human macrophages (2000) (0)
2.P.326 Short-term heterologous desensitization of platelet LDL receptor by high lipoprotein levels (1997) (0)
3.P.385 25-hydroxy-and 27-hydroxycholesterol enhance a hypoxia-induced IL-8 expression in human macrophages (1997) (0)
Prevalence of familial hypercholesterolemia in individuals with premature coronary syndrome (2015) (0)
48 INHIBITION OF ALOX15B REDUCES INFLAMMATION IN ATHEROSCLEROSIS-PRONE MICE (2011) (0)
[European guidelines for lipid treatment are tailored according to risk level]. (2012) (0)
Cell adhesion molecules and secretory type II phospholipase A2 in relation to risk factors and carotid atherosclerosis (2000) (0)
Mo-W7:6 Tagging SNP haplotype analysis of the secretory PLA2-IIA gene PLA2G2A shows strong association with serum levels of SPLA2IIA (2006) (0)
Multivariate Analysis of Serum Apolipoprotein Levels and Other Risk Factors for Myocardial Infarctions (1985) (0)
In Memoriam: Sven-Olof Olofsson (1947-2011)1 (2012) (0)
Effects of oxidized LDL and oxysterols on the transcription factors NF-kB and AP-1 in human macrophages, after exposure to lipopolysaccharide (1994) (0)
Identification of a new genetic determinant of familial hypercholesterolemia (FH) (2018) (0)
Plasma Levels of (cid:1) -Amyloid (1-40) , (cid:1) -Amyloid (1-42) , and Total (cid:1) -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins (2004) (0)
The 12th annual European Conference on Vascular Biology. (1992) (0)
Do modified lipids and lipoproteins drive the inflammation in unstable coronary plaques? (2008) (0)
Measurement of Antioxidant Activity in Lipoproteins Using Enhanced Chemiluminescence (1994) (0)
Isolation of Two Nonidentical Polypeptides from Apolipoprotein B of Human Plasma (1985) (0)
Tu-P7:190 Stearate induces proinflammatory cytokine secretion in macrophages (2006) (0)
TACG_A_202942 71..78 (2019) (0)
Psychological effects of cpr training of myocardial infarction patients and their relatives (1992) (0)
Treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 does not increase lipoprotein(A) concentrations (1998) (0)
Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia (2016) (0)
4.P.4 Hypoxia is present within the arterial wall in vivo (1997) (0)
[PCSK9 inhibitors reduces LDL cholesterol by 60 percent]. (2017) (0)
[Determination of apolipoproteins: An important tool for prevention and treatment of cardiovascular diseases]. (2007) (0)
W09.258 Elevated levels of serum inflammation markers and monocytic surface receptors in women with the metabolic syndrome (2004) (0)
Subject Index Vol. 111, 2008 (2008) (0)
The Molecular Basis for Lipoprotein Interaction with Vascular Tissue (1991) (0)
Th-P15:50 Characterization of LDL-associated proteins in the dyslipidemia of type 2 diabetes and the metabolic syndrome (2006) (0)
3.P.170 Butylated hydroxytoluene and N-acetylcysteine decrease the production of tumor necrosis factor-α from human alveolar macrophages (1997) (0)
LOVASTATIN AND MYOPATHY. AUTHORS' REPLY (1994) (0)
PO9-271 OVEREXPRESSION OF 15-LIPOXYGENASE TYPE 2 IN MACROPHAGES INCREASES MACROPHAGE CHEMOKINE SECRETION AND T CELL MIGRATION (2007) (0)
[Quantitative measurement of atherosclerosis. Development of ultrasound techniques is worth while]. (1993) (0)
[New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects]. (2006) (0)
[Drug treatment of hypercholesterolemia. Confusing discrepancies in guidelines of an advertising campaign]. (1990) (0)
Low SNP score for polygenic hypercholesterolemia associates with poor metabolic profile (2018) (0)
Guidelines on CVD prevention: confusing or complementary? (2013) (0)
MS25 LDL-ASSOCIATED LYSOZYME AND apoJ-SPECIFIC DISTRIBUTION IN INDIVIDUALS WITH TYPE 2 DIABETES AND THE METABOLIC SYNDROME (2010) (0)
Corrección en el artículo «Comentarios a la guía ESC/EAS 2016 sobre el tratamiento de las dislipemias», Rev Esp Cardiol. 2017;70:72-77 (2018) (0)
43 Automated enhanced chemilnminescence technique in evaluating total antioxidativ capacity in human serum (1997) (0)
German Camejo (1936-2021). (2022) (0)
German Camejo (1936-2021). (2022) (0)
Expression of PAF receptors and PAF-acetylhydrolase in the arterial wall. Relevance to inflammatory response in atherogenesis* (1999) (0)
UP- AND DOWNSTREAM STRUCTURAL DIFFERENCES IN CAROTID PLAQUE COMPOSITION - IMPLICATIONS FOR STUDIES OF HUMAN SYMPTOMATIC CAROTID PLAQUES (2008) (0)
[Elderly benefit from lower LDL-cholesterol]. (2021) (0)
[Familial hypercholesterolemia--undertreated and often fatal]. (2009) (0)
3.P.116 Auto-antibody titers against oxidized LDL are not elevated in a group of patients with familial hypercholesterolemia compared to controls (1997) (0)
[Equal key messages in guidelines for lipids for cardiovascular prevention. European and American recommendations are based on risk stratification]. (2014) (0)
First annual Copenhagen atherosclerosis conference (1995) (0)
2.W18.5 Lipid oxidation products as regulators of macrophage function in atherosclerosis (1997) (0)
PO9-217 PALMITATE INDUCES PROINFLAMMATORY CYTOKINE SECRETION IN HUMAN MACROPHAGES VIA ACTIVATION OF P38 AND JNK KINASES (2007) (0)
[Is there a reason to take the cholesterol deniers seriously?]. (2008) (0)
The effect of metoprolol CR/XL on atherosclerosis (2000) (0)
25-hydroxycholesterol increases an LPS-induced IL-1β protein expression in human macrophages (2000) (0)
Oxysterols increase A lipopolysaccharide-induced interleukin-1β protein expression in human monocyte-derived macrophages (1999) (0)
Tu-P7:188 Palmitate induces proinflammatory cytokine secretion in macrophages (2006) (0)
[Apolipoprotein B plays a central role in atherogenesis and lipid metabolism]. (1989) (0)
Antibodies against oxidized LDL in relation to cell-adhesion molecules, secretory type II phospholipase A2 and carotid atherosclerosis (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Olov Wiklund?

Olov Wiklund is affiliated with the following schools:

Uppsala University
University of Gothenburg
Karolinska Institute

Olov Wiklund's Academic­Influence.com Rankings

Why Is Olov Wiklund Influential?

Olov Wiklund's Published Works

Published Works

What Schools Are Affiliated With Olov Wiklund?

Olov Wiklund's AcademicInfluence.com Rankings